Source:http://linkedlifedata.com/resource/pubmed/id/10492165
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1999-10-27
|
| pubmed:abstractText |
Prognostic relevance of cell proliferation markers was evaluated in 27 glioma patients. By 1) flow cytometry (FCM), i.e., S-phase fraction (SPF), and BrdUrd-labeling index (LIfcm); 2) immunohistochemistry (IHC), i.e., BrdUrd-labeling index (LIihc) and MIB-1 immunoreactivity (MIB-1 LIihc); and 3) histologic examination, i.e., the presence or absence of cells in mitoses, were assessed. A longer local progression free survival (LPFS) was significantly associated with low SPF, low LIfcm, and low MIB-1 LIihc. For LIihc, no significant association was found. LIfcm appeared to be a more promising prognosticator than MIB-1 LIihc. In comparison with this marker, the presence or absence of mitotic figures appeared to be an even stronger prognosticator. Prognostic significance of LIfcm appeared to be of importance in low-grade gliomas. The number of patients in our study is limited. Our findings were: 1) the presence or absence of cells in mitoses (M-phase activity) appeared to be of more prognostic significance than LIfcm (S-phase activity) and MIB-1 LIihc (non-G0-phase activity); 2) of the tested experimental cell proliferation markers, LIfcm appeared to be of more prognostic significance than MIB-1 LIihc, SPF, and LIihc; and 3) LIfcm is likely to be an important prognosticator in low-grade gliomas and is, therefore, not definitive and only of potential interest.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Nuclear,
http://linkedlifedata.com/resource/pubmed/chemical/Bromodeoxyuridine,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Ki-67 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1065-7541
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
243-8
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10492165-Adult,
pubmed-meshheading:10492165-Aged,
pubmed-meshheading:10492165-Antigens, Nuclear,
pubmed-meshheading:10492165-Brain Neoplasms,
pubmed-meshheading:10492165-Bromodeoxyuridine,
pubmed-meshheading:10492165-DNA, Neoplasm,
pubmed-meshheading:10492165-Disease-Free Survival,
pubmed-meshheading:10492165-Female,
pubmed-meshheading:10492165-Flow Cytometry,
pubmed-meshheading:10492165-Glioma,
pubmed-meshheading:10492165-Humans,
pubmed-meshheading:10492165-Immunoenzyme Techniques,
pubmed-meshheading:10492165-Ki-67 Antigen,
pubmed-meshheading:10492165-Male,
pubmed-meshheading:10492165-Middle Aged,
pubmed-meshheading:10492165-Mitosis,
pubmed-meshheading:10492165-Mitotic Index,
pubmed-meshheading:10492165-Nuclear Proteins,
pubmed-meshheading:10492165-Prognosis,
pubmed-meshheading:10492165-Retrospective Studies,
pubmed-meshheading:10492165-S Phase
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Prognostic relevance of MIB-1 immunoreactivity, S-phase fraction, 5-bromo-2'-deoxyuridine labeling indices, and mitotic figures in gliomas.
|
| pubmed:affiliation |
Department of Radiotherapy, University Hospital, Utrecht, The Netherlands. h.struikmans@radcl.ruu.nl
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|